McKesson says states seek $21 billion from drug distributors in opioid settlement
Reuters
Published Nov 03, 2020 09:59AM ET
Updated Nov 03, 2020 12:10PM ET
By Nate Raymond
(Reuters) - McKesson Corp (N:MCK) on Tuesday said it and two other major U.S. drug distributors could be expected to pay up to $21 billion under a new proposal to resolve thousands of lawsuits alleging they helped fuel the U.S. opioid crisis.
McKesson and rivals AmerisourceBergen Corp (N:ABC) and Cardinal Health Inc (N:CAH) last year proposed paying a combined $18 billion to resolve the roughly 3,200 lawsuits, with drugmaker Johnson & Johnson (N:JNJ) paying another $4 billion.
That proposal, part of a settlement framework negotiated with four state attorneys general, met resistance from lawyers for local governments and several states, leading to further talks. J&J on Oct. 13 said it would now contribute $5 billion.
San Francisco-based McKesson in a quarterly report said under the new $21 billion settlement framework proposed by attorneys general, it would pay about $8 billion over 18 years.
The proposal is subject to further negotiations, and McKesson said it "has not reached a point where settlement is probable."
"Communities are desperately in need of the relief this deal would provide," said Laura Brewer, a spokeswoman for North Carolina Attorney General Josh Stein, who is involved in the settlement talks.
AmerisourceBergen and Cardinal Health declined to comment.
The lawsuits, largely filed by states, counties and cities, seek to hold drug companies responsible for an opioid addiction epidemic that according to U.S. government data resulted in 450,000 overdose deaths from 1999 to 2018.
The lawsuits accuse drugmakers of deceptively marketing opioids and distributors of ignoring red flags indicating the prescription painkillers were being diverted for improper uses. They deny wrongdoing.
McKesson said the proposed settlement also calls for the distributors to make changes to their anti-diversion programs.
OxyContin maker Purdue Pharma and generic painkiller manufacturer Mallinckrodt Plc (N:MNK) previously filed for bankruptcy protection in connection with their own multibillion-dollar proposals to resolve opioid lawsuits against them.
Get The News You Want
Written By: Reuters
Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.